Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

CME vs. Upstart: Which Financial Stock Is a Better Buy for 2027?

CME's roughly $4 billion profit and near-zero leverage stand in contrast to Upstart's 64% revenue surge, but the lending specialist's leverage and negative free cash flow tell a different story.

CME Group (CME) and Upstart (UPST) are two distinct companies within the financial services sector. CME provides critical infrastructure for global risk management through derivatives trading and clearing services, while Upstart utilizes AI technology to redefine personal credit scoring. In 2025, CME reported nearly $6.5 billion in revenue, a 6.4% increase from the previous year, with net income close to $4 billion.

Upstart, on the other hand, reported $1 billion in revenue, a 64% increase from the prior year, and net income of $53.6 million. While CME has a low debt-to-equity ratio of approximately 0.1, indicating minimal total debt relative to shareholder equity, Upstart's ratio is significantly higher at roughly 2.3, suggesting higher liabilities compared to shareholder equity.

CME Group faces risks from market volatility, cybersecurity threats, and intense competition, while Upstart's business relies heavily on a limited number of lending partners and faces potential risks from its AI models. CME Group's stock trades at a lower forward P/E ratio, indicating a more conservative valuation relative to future earnings.

Considering their business models, risks, and valuation, CME Group could be a more suitable investment for long-term goals in 2027.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at fool.com →

More in Finance & Markets

More from Wednesday 18 November →